Literature DB >> 26666938

Risk Factors and Outcomes for Intestinal Carriage of AmpC-Hyperproducing Enterobacteriaceae in Intensive Care Unit Patients.

Simon Poignant1, Jérôme Guinard2, Aurélie Guigon2, Laurent Bret2, Didier-Marc Poisson2, Thierry Boulain1, François Barbier3.   

Abstract

In a cohort of 1,209 intensive care unit (ICU) patients, the prevalence of intestinal colonization with high-level expressed AmpC cephalosporinase-producing Enterobacteriaceae (HLAC-PE) rose steadily from 2% at admission to 30% in patients with lengths of stay (LOS) exceeding 4 weeks. In multivariate analysis, LOS was the main predictor of carriage acquisition after adjustment on antimicrobial exposure. HLAC-PE infection occurred in 15% of carriers. Carriage and infection were associated with a marked increase in carbapenem consumption.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26666938      PMCID: PMC4775921          DOI: 10.1128/AAC.02101-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  J Clin Epidemiol       Date:  2008-04       Impact factor: 6.437

2.  Strategies to reduce curative antibiotic therapy in intensive care units (adult and paediatric).

Authors:  Cédric Bretonnière; Marc Leone; Christophe Milési; Bernard Allaouchiche; Laurence Armand-Lefevre; Olivier Baldesi; Lila Bouadma; Dominique Decré; Samy Figueiredo; Rémy Gauzit; Benoît Guery; Nicolas Joram; Boris Jung; Sigismond Lasocki; Alain Lepape; Fabrice Lesage; Olivier Pajot; François Philippart; Bertrand Souweine; Pierre Tattevin; Jean-François Timsit; Renaud Vialet; Jean Ralph Zahar; Benoît Misset; Jean-Pierre Bedos
Journal:  Intensive Care Med       Date:  2015-06-03       Impact factor: 17.440

3.  Assessment of five screening strategies for optimal detection of carriers of third-generation cephalosporin-resistant Enterobacteriaceae in intensive care units using daily sampling.

Authors:  P Grohs; I Podglajen; E Guerot; F Bellenfant; A Caumont-Prim; G Kac; B Tillecovidin; E Carbonnelle; G Chatellier; G Meyer; J Y Fagon; L Gutmann
Journal:  Clin Microbiol Infect       Date:  2014-07-25       Impact factor: 8.067

Review 4.  Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review.

Authors:  Marya D Zilberberg; Joyce Chen; Samir H Mody; Andrew M Ramsey; Andrew F Shorr
Journal:  BMC Pulm Med       Date:  2010-08-26       Impact factor: 3.317

5.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

Review 6.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

7.  Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission.

Authors:  Matthaios Papadimitriou-Olivgeris; Markos Marangos; Fotini Fligou; Myrto Christofidou; Christina Bartzavali; Evangelos D Anastassiou; Kriton S Filos
Journal:  J Antimicrob Chemother       Date:  2012-08-26       Impact factor: 5.790

8.  Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.

Authors:  Mark J Siedner; Alicia Galar; Belisa B Guzmán-Suarez; David W Kubiak; Nour Baghdady; Mary Jane Ferraro; David C Hooper; Thomas F O'Brien; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2014-03-18       Impact factor: 9.079

Review 9.  Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.

Authors:  Matteo Bassetti; Jan J De Waele; Philippe Eggimann; Josè Garnacho-Montero; Gunnar Kahlmeter; Francesco Menichetti; David P Nicolau; Jose Arturo Paiva; Mario Tumbarello; Tobias Welte; Mark Wilcox; Jean Ralph Zahar; Garyphallia Poulakou
Journal:  Intensive Care Med       Date:  2015-03-20       Impact factor: 17.440

10.  Mechanisms of antimicrobial resistance in Gram-negative bacilli.

Authors:  Étienne Ruppé; Paul-Louis Woerther; François Barbier
Journal:  Ann Intensive Care       Date:  2015-08-12       Impact factor: 6.925

View more
  3 in total

Review 1.  Understanding resistance.

Authors:  François Barbier; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2016-09-19       Impact factor: 17.440

Review 2.  Rationalizing antimicrobial therapy in the ICU: a narrative review.

Authors:  Jean-François Timsit; Matteo Bassetti; Olaf Cremer; George Daikos; Jan de Waele; Andre Kallil; Eric Kipnis; Marin Kollef; Kevin Laupland; Jose-Artur Paiva; Jesús Rodríguez-Baño; Étienne Ruppé; Jorge Salluh; Fabio Silvio Taccone; Emmanuel Weiss; François Barbier
Journal:  Intensive Care Med       Date:  2019-01-18       Impact factor: 17.440

Review 3.  Empiric Treatment in HAP/VAP: "Don't You Want to Take a Leap of Faith?"

Authors:  Khalil Chaïbi; Gauthier Péan de Ponfilly; Laurent Dortet; Jean-Ralph Zahar; Benoît Pilmis
Journal:  Antibiotics (Basel)       Date:  2022-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.